Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST‐2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we present a ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Pemmaraju, Naveen, Harrison, Claire, Gupta, Vikas, Verstovsek, Srdan, Scott, Bart, Oh, Stephen T., Palandri, Francesca, Al‐Ali, Haifa Kathrin, Sobas, Marta, McMullin, Mary Frances, Mesa, Ruben, Buckley, Sarah, Roman‐Torres, Karisse, Vannucchi, Alessandro, Yacoub, Abdulraheem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713029/
https://www.ncbi.nlm.nih.gov/pubmed/36467816
http://dx.doi.org/10.1002/jha2.591
Descripción
Sumario:The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST‐2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we present a risk‐adjusted safety analysis of event rates accounting for different time on treatment. While the rate of overall events was higher on pacritinib compared to BAT, the rate of fatal events was lower, and there was no excess in bleeding, cardiac events, secondary malignancy, or thrombosis on pacritinib, including in patients with severe thrombocytopenia.

Ejemplares similares